New Digital System Helps Personalize Antidepressant Treatment

Finding the right medication for major depressive disorder often involves significant trial and error. This process frequently leads to patients stopping their therapy too early. However, recent findings from the PETRUSHKA trial suggest that clinicians can now use web-based tools to personalize antidepressant treatment more effectively. This innovative approach combines clinical data with patient preferences to optimize outcomes from the very first prescription.

Researchers conducted a multicenter, randomized clinical trial involving 540 participants across Brazil, Canada, and the UK. Specifically, they compared an evidence-based clinical decision-support system, known as the PETRUSHKA tool, against usual care. Consequently, the results demonstrated a clear advantage for the personalized approach. Patients in the intervention group were significantly more likely to remain on their prescribed medication compared to those receiving standard care.

Better Outcomes Through the Ability to Personalize Antidepressant Treatment

The study primarily measured treatment discontinuation rates at eight weeks. Findings showed that only 17% of participants using the PETRUSHKA tool stopped their medication, whereas 27% in the usual care group discontinued therapy. Furthermore, the tool successfully reduced discontinuation specifically due to adverse events. Therefore, using data-driven insights helps clinicians select medications that patients tolerate better over the long term.

Beyond adherence, the trial observed notable improvements in clinical symptoms. At 24 weeks, patients in the PETRUSHKA group reported lower depression and anxiety scores on the PHQ-9 and GAD-7 scales. Additionally, the tool empowers patients by incorporating their preferences regarding potential side effects. This shared decision-making process fosters a stronger therapeutic alliance and improves the overall quality of care.

Clinicians often face challenges when choosing between the dozens of available antidepressants. Most prescriptions in primary care currently rely on a small handful of familiar drugs. However, the PETRUSHKA system uses advanced algorithms to identify the most suitable options for each unique individual. This shift toward precision psychiatry represents a major milestone in mental health management.

Frequently Asked Questions

How does the PETRUSHKA tool help personalize antidepressant treatment?

The tool analyzes a patient's age, gender, and symptom severity alongside their personal concerns about side effects. Consequently, it generates a list of antidepressants that are most likely to be both effective and well-tolerated for that specific individual.

Does this tool reduce the side effects of antidepressants?

Yes, the trial found that patients using the PETRUSHKA tool were 40% less likely to stop their medication due to adverse effects. By matching the drug profile to the patient's sensitivity, clinicians can minimize bothersome reactions.

Is the PETRUSHKA tool available for general practitioners?

The study highlights its efficacy in both primary and secondary care settings. As digital health tools evolve, such systems are expected to become more integrated into routine clinical workflows to assist GPs in mental health management.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

• Cipriani A et al. A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2026 Mar 04. doi: 10.1001/jama.2026.1327. PMID: 41779422.


• NIHR Oxford Health Biomedical Research Centre. Digital tool that personalises antidepressant treatment significantly improves outcomes of people with depression. nihr.ac.uk. Published March 04, 2026.


• University of Oxford Department of Psychiatry. Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. bmj.com. Published October 23, 2019.